Free tool
FAERS Monitor: Voranigo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218784 or its brand name (Voranigo, Vorasidenib). Reports on generic versions are filed under their own applications.
Reports
612
Serious
463
76% of reports
Hospitalization
135
Death reported
12
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- alanine aminotransferase increased83
- aspartate aminotransferase increased68
- fatigue67
- malignant neoplasm progression46
- seizure41
- headache39
- nausea38
- hepatic cytolysis34
- hepatic enzyme increased34
- gamma-glutamyltransferase increased28
- liver function test increased24
- hepatotoxicity21
- drug-induced liver injury20
- diarrhoea18
- blood bilirubin increased17
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 2 |
| 2024 | 42 |
| 2025 | 313 |
| 2026 | 255 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,547 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatic cytolysisSignal | 34 | 91.9 | 66.3 | 2,960 |
| alanine aminotransferase increasedSignal | 83 | 46.5 | 38.1 | 3,658 |
| aspartate aminotransferase increasedSignal | 68 | 44.1 | 35.2 | 2,822 |
| gamma-glutamyltransferase increasedSignal | 28 | 43.5 | 30.3 | 1,120 |
| liver function test increasedSignal | 24 | 38.5 | 26.0 | 839 |
| hepatotoxicitySignal | 21 | 32.4 | 21.3 | 609 |
| drug-induced liver injurySignal | 20 | 21.9 | 14.2 | 379 |
| blood bilirubin increasedSignal | 17 | 21.6 | 13.5 | 315 |
| hepatic enzyme increasedSignal | 34 | 17.1 | 12.4 | 502 |
| malignant neoplasm progressionSignal | 46 | 15.4 | 11.7 | 610 |
| seizureSignal | 41 | 12.2 | 9.1 | 413 |
| fatigueSignal | 67 | 3.0 | 2.4 | 88 |
| headacheSignal | 39 | 2.1 | 1.6 | 23 |
| nausea | 38 | 1.7 | 1.2 | 9 |
| diarrhoea | 18 | 1.0 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.